ClinicalTrials.gg
RecruitingNCT04918186IPROCUpdated Nov 16, 2026

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

A Phase 2 interventional study of Durvalumab and BA3011 in Ovarian Cancer, sponsored by Canadian Cancer Trials Group. Recruiting at 6 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Canadian Cancer Trials Group · Phase 2, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.
Updated Nov 16, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 273 studies in Ovarian Neoplasms with a site in Canada — 47 open to participants now, 89 under way, 27 of them phase 3. Ovarian Neoplasms · Canada.

Planned enrollment
168th of 239
60 · median 133
Started
2022
with 17 others
Phase 2
90 of 273
11 open now
Primary completion
2026-12
later than 35 of 88 live
Registered
207th of 273
by date

Among the 273 studies in Ovarian Neoplasms with a site in Canada, this one is the 168th largest by planned enrollment of the 239 interventional ones that give a count, is one of 18 that started in 2022, is one of 90 in phase 2, reaches primary completion later than 35 of the 88 other live ones, and was the 207th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

47 of the 273 studies in Ovarian Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 273 studies in Ovarian Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

Read the detailed description

This study is being conducted to determine if this approach is better or worse than the standard of care for ovarian cancer. The standard of care is defined as care most people get for ovarian cancer.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • This study will enroll women with platinum resistant high grade serous ovarian cancer.
  • This study is open to minorities as appropriate but is not designed to measure differences in intervention effects.
  • All patients must be registered for screening prior to study enrollment, however, if biomarker testing results are not required prior to enrollment to a substudy, then enrollment can proceed immediately. CCTG will advise sites when biomarker testing results are required prior to substudy enrollment.

Additional Criteria To Be Met Prior To Sub-study Enrollment All patients must fulfill all of the following criteria to be eligible for enrollment to the study. Additional eligibility criteria and relevant timings that are specific to a substudy are listed in each substudy specific protocol.

  • Patients must have platinum resistant high grade serous carcinoma of ovarian, fallopian tube or peritoneal origin defined as progression within 6 months of last platinum containing chemotherapy. Histological confirmation of the original primary tumour is required.
  • All patients must have as defined by 1.1. The criteria for defining measurable disease are as follows:

    • Chest x-ray ≥ 20 mm
    • CT scan (with slice thickness of 5 mm) ≥ 10 mm - longest diameter
    • Physical exam (using calipers) ≥ 10 mm
    • Lymph nodes by CT scan ≥ 15 mm - measured in short axis
  • Patients must have at least one disease site amendable to pre and on-treatment and must consent to undergo these tumour biopsies.
  • Prior surgery is permitted provided that a minimum of at least 28 days have elapsed between any major surgical procedure and date of enrollment, and that wound healing has occurred.
  • Systemic Therapy:

    • There is no limit to the number of prior regimens for platinum-sensitive disease. However, patients may not have received more than one cytotoxic chemotherapy regimen for platinum-resistant disease.
    • Patients may have received non-cytotoxic therapies (excluding agents targeted by the planned substudy). Refer to each substudy protocol for exclusions.
    • Prior treatment with an (ICI) is permissible providing the ICI was not discontinued for severe or recurrent severe toxicity (including myocarditis, or other myocardiotoxicity, encephalitis, colitis, diarrhea, pancreatitis, hypo/hyper thyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, Guillain-Barre, myositis/polymyositis, hepatitis, nephritis, Type 1 diabetes, thrombocytopenia)
    • A minimum of 4 weeks must have elapsed between last dose of prior therapy and enrollment.
    • All reversible prior toxicity must have recovered to grade ≤ 1 (consult CCTG in the case of irreversible toxicity)
  • Other Therapy:

    • Radiation, endocrine therapy, or other non-anti-cancer agents are permitted provided a minimum of 28 days (4 weeks) have elapsed between the last dose and enrollment. Exceptions may be made for low-dose, non-myelosuppressive radiotherapy after consultation with CCTG.
  • performance status 0 or 1 and have a ≥ 3 months.
  • Patients must be ≥ 18 years of age.
  • All patients must have consented to:

    1. Release of tumour block from their primary or tumour, if available. If archival tissue is unavailable, a tumour biopsy is required during screening. The centre/pathologist must have agreed to the submission of the specimen(s).
    2. Pre and on treatment tumour biopsies:
  • Core needle (a minimum of 6 core samples are required) or excisional biopsies or resected tissue specimens are required.
  • CCTG will advise sites when biomarker testing results are required prior to enrollment
  • Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the trial.
  • Patients must have adequate organ and marrow function measured within 7 days prior to enrollment including;
  • Absolute neutrophils ≥ 1.5 x 10\^9/L (1500/µL)
  • ≥ 100 x 10\^9/L (100 x 103/µL)
  • ≥90g/L* (10.0 g/dL) with no blood transfusions in the past 28 days.
  • ≤ 1.5 x (upper limit of normal)**
  • \& ALT ≤ 2.5 x ULN; if patient has liver metastases ≤ 5.0 x ULN
  • Serum creatinine or: ≤ 1.5 x ULN / >50 mL/min
  • Albumin >35 g/L (3.5 g/dL)
  • /PTT INR \< 1.7 or PTT \< 4 seconds above control
  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
  • Patients must be accessible for treatment and follow up. Patients enrolled on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.
  • Patient must agree to return to their primary care facility for any adverse events, response assessments and follow-up, which may occur through the course of the trial.
  • In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient enrollment.
  • Women of will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of other may be eligible if curatively treated and/or the malignancy does not affect the determination of safety or efficacy of the regimen (must be confirmed with CCTG prior to enrollment).
  • Patients with uncontrolled or serious illnesses, or medical conditions which could cause unacceptable safety risks or would not permit the patient to be managed according to the protocol or substudy. This includes but is not limited to:

    • history of intra-abdominal abscess within 3 months prior to starting treatment;
    • other active infection or chronic liver disease requiring systemic therapy;
    • active or known (HIV), or infection on antiviral treatment or with detectable viral load;
    • history of interstitial lung disease, non-infectious pneumonitis or severe pulmonary disease exacerbated by pneumonitis or uncontrolled diseases, including pulmonary fibrosis, acute lung disease, etc.
    • pleural, pericardial, and/or peritoneal effusion (e.g., effusion affecting normal organ function and/or requiring percutaneous drainage or diuretic control);
    • disease requiring chronic use;
    • prior history of a stroke or within the last 6 months;
    • history of significant cardiac disease within 6 months prior to starting treatment such as myocardial infarction, unstable angina, cardiomyopathy, congestive heart failure;
    • prior stem cell transplantation or organ transplantation.
  • Central nervous system

    • Symptomatic uncontrolled requiring corticosteroid treatment.
    • History of spinal cord compression unless after definitive treatment the patient has clinically stable disease (SD) for at least 28 days prior to starting investigational agent(s).
  • Pregnant or lactating (breastfeeding) women.
  • Patients receiving concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents.
  • Active or prior documented autoimmune or inflammatory disorders, including: inflammatory bowel disease (e.g. colitis or Crohn's disease), diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea, systemic lupus erythematosus, Sarcoidosis syndrome, Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment.
  • Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune conditions only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions considered to be of low risk for recurrence are permitted to enroll.
  • Patients must not have been administered a ≤ 4 weeks before enrollment.

Note: Seasonal vaccines for influenza are general inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and not allowed.

  • (using the Fridericia correction calculation) >470 msec or >450 msec if history of additional risk factors for Torsade de Pointe (e.g. heart failure, hypokalemia, family history of Long QT Syndrome) or use of concomitant medications that prolong the QT/QTc interval.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Durvalumab + BA3011 (Arm Closed)

    Drug: Durvalumab · Drug: BA3011

  • Experimental
    Durvalumab + BA3021 (Arm Closed)

    Drug: Durvalumab · Drug: BA3021

  • Experimental
    ENB-003 + Toripalimab

    Drug: ENB003 · Drug: Toripalimab

Interventions

06

What researchers measure

Primary outcomes

  1. To efficiently identify based on objective response rate (ORR), by investigator assessment using RECIST 1.1, promising immunotherapy combinations for the treatment of high grade serous ovarian cancer for later validation in randomized trials

    Time frame: 36 months

Secondary outcomes

  1. Evaluate ORR by investigator assessment using RECIST 1.1

    Time frame: 36 months

  2. Determine progression-free survival of immunotherapy regimens (RECIST 1.1 and iRECIST)

    Time frame: 36 months

  3. Determine overall-survival of immunotherapy regimens (RECIST 1.1 and iRECIST)

    Time frame: 36 months

  4. Number and severity of adverse events

    Time frame: 36 months

07

Study locations

1 of 6 sites recruiting
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
    • John Moroney · Contact773-834-4732
  • BCCA - Kelowna
    Kelowna, British Columbia V1Y 5L3, Canada
    Not yet recruiting
    • Susan Ellard · Contact250 712-3900
  • BCCA - Vancouver
    Vancouver, British Columbia V5Z 4E6, Canada
    Not yet recruiting
    • Anna Tinker · Contact604 877-6000
  • Odette Cancer Centre
    Toronto, Ontario M4N 3M5, Canada
    Not yet recruiting
    • Helen MacKay · Contact416 480-5145
  • University Health Network
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
    • Stephanie Lheureux · Contact416 946-4501
  • CHUM-Centre Hospitalier de l'Universite de Montreal
    Montreal, Quebec H2X 3E4, Canada
    Not yet recruiting
    • Diane Provencher · Contact514 890-8444
08

References and documents

Publications

  • MacKay HJ, Tinker AV, Nelson BH, Zamarin D, Odunsi AO, Lheureux S, Ellard S, Smrke A, Gaudreau PO, Faulkner T, Upadhaya S, Zhou A, Tu W, Dancey J. CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021). Cancer Treat Res Commun. 2026 May 28;48:101260. doi: 10.1016/j.ctarc.2026.101260. Online ahead of print. PubMed 42225005 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's planned 55 months is close to that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2021
First posted
Jun 8, 2021
StartActual
May 3, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
across 2 updates, Nov 5, 2026 – Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    5 sites changed recruiting status (5 now not yet recruiting)
    Show 5 sites
    • BCCA - Kelowna · Kelowna, CanadaRecruiting→Not yet recruiting
    • BCCA - Vancouver · Vancouver, CanadaRecruiting→Not yet recruiting
    • Odette Cancer Centre · Toronto, CanadaRecruiting→Not yet recruiting
    • University Health Network · Toronto, CanadaRecruiting→Not yet recruiting
    • CHUM-Centre Hospitalier de l'Universite de Montreal · Montreal, CanadaRecruiting→Not yet recruiting
    + 1 other change: contact details
  2. Nov 5, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • BCCA - Kelowna · Kelowna, CanadaNot yet recruiting→Recruiting
    • BCCA - Vancouver · Vancouver, CanadaNot yet recruiting→Recruiting
    • Odette Cancer Centre · Toronto, CanadaNot yet recruiting→Recruiting
    • University Health Network · Toronto, CanadaNot yet recruiting→Recruiting
    • CHUM-Centre Hospitalier de l'Universite de Montreal · Montreal, CanadaNot yet recruiting→Recruiting
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04918186
Lead sponsor
Canadian Cancer Trials Group
Collaborators
Cancer Research Institute, New York City, AstraZeneca, BioAtla, Inc.
Responsible party
Sponsor
First posted
Jun 8, 2021
Start date
May 3, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Janet Dancey
Contact
jdancey@ctg.queensu.ca
613-533-6430
Pierre-Olivier Gaudreau
Contact
p-ogaudreau@ctg.queensu.ca
613-533-6430
Helen MacKay
study chair · Sunnybrook Health Sciences Centre, Toronto, Ontario Canada
Anna Tinker
study chair · BCCA - Vancouver Cancer Centre, BC Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozuriftamab vedotin

Start the discussion